Market Cap
US$12.6b
Last Updated
2019/11/17 00:18 UTC
Data Sources
Company Financials +
Executive Summary
STERIS plc provides infection prevention and other procedural products and services worldwide.
Snowflake
Fundamentals
Excellent balance sheet, good value and pays a dividend.
Similar Companies
Share Price & News
How has STERIS's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: STE has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
2.0%
STE
3.2%
US Medical Equipment
0.7%
US Market
1 Year Return
25.7%
STE
19.2%
US Medical Equipment
12.9%
US Market
Return vs Industry: STE exceeded the US Medical Equipment industry which returned 19.2% over the past year.
Return vs Market: STE exceeded the US Market which returned 12.9% over the past year.
Shareholder returns
| STE | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.0% | 3.2% | 0.7% |
| 30 Day | 3.8% | 4.4% | 4.4% |
| 90 Day | -2.9% | 3.6% | 7.2% |
| 1 Year | 27.0%25.7% | 20.2%19.2% | 15.4%12.9% |
| 3 Year | 133.5%124.6% | 85.9%80.2% | 49.1%39.5% |
| 5 Year | 156.5%139.5% | 120.3%96.3% | 62.7%44.7% |
Price Volatility Vs. Market
How volatile is STERIS's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Here's What Analysts Are Forecasting For STERIS plc After Its Latest Second-Quarter Results1 week ago | Simply Wall St
Should You Be Adding STERIS (NYSE:STE) To Your Watchlist Today?3 weeks ago | Simply Wall St
These 4 Measures Indicate That STERIS (NYSE:STE) Is Using Debt SafelyValuation
Is STERIS undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: STE ($148.75) is trading below our estimate of fair value ($645.03)
Significantly Below Fair Value: STE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: STE is good value based on its PE Ratio (37.5x) compared to the Medical Equipment industry average (46.3x).
PE vs Market: STE is poor value based on its PE Ratio (37.5x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: STE is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: STE is good value based on its PB Ratio (3.9x) compared to the US Medical Equipment industry average (3.9x).
Next Steps
Future Growth
How is STERIS forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
18.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STE's forecast earnings growth (18.9% per year) is above the savings rate (2.7%).
Earnings vs Market: STE's earnings (18.9% per year) are forecast to grow faster than the US market (14.3% per year).
High Growth Earnings: STE's earnings are forecast to grow, but not significantly.
Revenue vs Market: STE's revenue (5.8% per year) is forecast to grow slower than the US market (7.3% per year).
High Growth Revenue: STE's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: STE's Return on Equity is forecast to be low in 3 years time (15%).
Next Steps
Past Performance
How has STERIS performed over the past 5 years?
25.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STE has high quality earnings.
Growing Profit Margin: STE's current net profit margins (11.6%) are lower than last year (11.7%).
Past Earnings Growth Analysis
Earnings Trend: STE's earnings have grown significantly by 25.2% per year over the past 5 years.
Accelerating Growth: STE's earnings growth over the past year (6.4%) is below its 5-year average (25.2% per year).
Earnings vs Industry: STE earnings growth over the past year (6.4%) underperformed the Medical Equipment industry 28.3%.
Return on Equity
High ROE: STE's Return on Equity (10.4%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is STERIS's financial position?
Financial Position Analysis
Short Term Liabilities: STE's short term assets ($1.0B) exceeds its short term liabilities ($428.0M)
Long Term Liabilities: STE's short term assets (1.0B) do not cover its long term liabilities (1.5B)
Debt to Equity History and Analysis
Debt Level: STE's debt to equity ratio (36.7%) is considered satisfactory
Reducing Debt: STE's debt to equity ratio has reduced from 58% to 36.7% over the past 5 years.
Debt Coverage: STE's debt is well covered by operating cash flow (48.2%).
Interest Coverage: STE's interest payments on its debt are well covered by EBIT (14x coverage).
Balance Sheet
Inventory Level: STE has a high level of physical assets or inventory.
Debt Coverage by Assets: STE's debt is not covered by short term assets (assets are 0.9x debt).
Next Steps
Dividend
What is STERIS's current dividend yield, its reliability and sustainability?
0.99%
Current Dividend Yield
Upcoming Dividend Payment
Purchase STERIS before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: STE's dividend (0.99%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.42%).
High Dividend: STE's dividend (0.99%) is low compared to the top 25% of dividend payers in the US market (3.64%).
Stability and Growth of Payments
Stable Dividend: STE's dividends per share have been stable in the past 10 years.
Growing Dividend: STE's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (35%), STE's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: STE's dividends in 3 years are forecast to be well covered by earnings (23.2% payout ratio).
Next Steps
Management
What is the CEO of STERIS's salary, the management and board of directors tenure and is there insider trading?
6.3yrs
Average management tenure
CEO
Walt Rosebrough (65yo)
12.1yrs
Tenure
US$5,982,890
Compensation
Mr. Walter M. Rosebrough, Jr., also known as Walt, has been the Chief Executive Officer and President of STERIS plc since October 1, 2007. Mr. Rosebrough leads STERIS’ management team, assists the Board in ...
CEO Compensation Analysis
Compensation vs Market: Walt's total compensation ($USD5.98M) is below average for companies of similar size in the US market ($USD11.04M).
Compensation vs Earnings: Walt's compensation has been consistent with company performance over the past year.
Management Age and Tenure
6.3yrs
Average Tenure
50.5yo
Average Age
Experienced Management: STE's management team is seasoned and experienced (6.3 years average tenure).
Board Age and Tenure
10.5yrs
Average Tenure
65.5yo
Average Age
Experienced Board: STE's board of directors are seasoned and experienced ( 10.5 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 58,500 |
| Max Price | US$150.83 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 221,493 |
| Max Price | US$138.02 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 72,867 |
| Max Price | US$137.60 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 213,197 |
| Max Price | US$136.60 |
| Entity | Individual |
| Shares | 5,156 |
| Max Price | US$135.64 |
| Entity | Individual |
| Shares | 5,700 |
| Max Price | US$134.67 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Mike Tokich (50yo)
Senior VP & CFO
- Tenure: 11.7yrs
- Compensation: US$2.25m
Walt Rosebrough (65yo)
CEO, President & Director
- Tenure: 12.1yrs
- Compensation: US$5.98m
Kathie Bardwell (63yo)
Chief Compliance Officer & Senior VP
- Tenure: 11.7yrs
John Zangerle (52yo)
Senior VP
- Tenure: 6.3yrs
- Compensation: US$1.46m
Michiel de Zwaan (48yo)
VP & Chief HR Officer
- Tenure: 2.2yrs
Dan Carestio (46yo)
Senior VP & Chief Operating Officer
- Tenure: 1.3yrs
- Compensation: US$2.15m
Karen Burton (51yo)
Chief Accounting Officer
- Tenure: 2.8yrs
Julie Winter
Senior Director of Investor Relations
- Tenure: 0yrs
Stephen Norton
Senior Director of Corporate Communications
- Tenure: 0yrs
Cary Majors (44yo)
Vice President of North American Commercial Operations
- Tenure: 0yrs
- Compensation: US$1.21m
Board Members
Richard Breeden (69yo)
Independent Director
- Tenure: 11.6yrs
- Compensation: US$294.98k
David Lewis (68yo)
Independent Director
- Tenure: 9.3yrs
- Compensation: US$299.96k
Mohsen Sohi (60yo)
Chairman of the Board
- Tenure: 1.3yrs
- Compensation: US$399.85k
Jackie Kosecoff (70yo)
Independent Director
- Tenure: 16.1yrs
- Compensation: US$280.38k
Cynthia Feldmann (66yo)
Independent Director
- Tenure: 14.7yrs
- Compensation: US$279.81k
Richard Steeves (57yo)
Independent Director
- Tenure: 4yrs
- Compensation: US$294.96k
Nirav Shah (47yo)
Independent Director
- Tenure: 1.5yrs
- Compensation: US$339.99k
Walt Rosebrough (65yo)
CEO, President & Director
- Tenure: 12.1yrs
- Compensation: US$5.98m
Company Information
STERIS plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: STERIS plc
- Ticker: STE
- Exchange: NYSE
- Founded: 1985
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$12.611b
- Shares outstanding: 84.78m
- Website: https://www.steris.com
Number of Employees
Location
- STERIS plc
- 70 Sir John Rogerson’s Quay
- Dublin 2
- Dublin
- D02 R296
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| STE | NYSE (New York Stock Exchange) | Yes | New Common Stock | US | USD | Jun 1992 |
| 2TG | DB (Deutsche Boerse AG) | Yes | New Common Stock | DE | EUR | Jun 1992 |
| 0XI8 | LSE (London Stock Exchange) | Yes | New Common Stock | GB | USD | Jun 1992 |
Biography
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied S ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/17 00:18 |
| End of Day Share Price | 2019/11/15 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.